Skip to main content

Table 5 Descriptive statistics of the length of treatment per treatment group

From: Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17–30 months

Group

Min

1st Quartile

Median

Mean

3rd Quartile

Max

Continued

17

21

25

25.23

29

30

Stopped

1

6

8

8.61

11

24